Translational mihondrial medicine applies the knowledge of experimental medicine in clinical practice, it is a prospective direction of the development of mihondrial medicine. The monograph "Translational Mihondrial Medicine" was created on the basis of rapidly developing new information about mihondrial diseases and their disorders, is a revised and supplemented edition of the monographs: "Mihondrial Medicine", ed. A. Gvozdjáková, Springer, 2008 and "Recent Advances in Mihondrial Medicine and Coenzyme Q10", eds. A. Gvozdjáková, G. Cornélissen, RB Singh, NOVA Science, USA, 2018. The monograph was created as part of the book series "Advances in biochemistry in health and disease", edited by prof. Naranjan Dhalla of Winnipeg, for which we are grateful.
The book"Translational Mihondrial Medicine" contributes to the elucidation of the pathobiochemical mechanisms of various diseases, provides current information on the prospective application of the latest diagnostic approaches and targeted therapy of mihondrial diseases.
Perspective mtDNA diagnostic methods include new technologies based on NGS (Next Generation Sequencing) to identify new genes associated with mihondrial diseases. With the help of the high resolution respirometry method (HRR), it is possible to record even the most subtle deviations of the bioenergetics of mihondria in blood cells, it contributes to the monitoring of the used daily doses of drugs in patients with various diseases. Determination of the endogenous level of coenzyme Q10 (CoQ10) in platelets is a key method to improve the diagnosis and targeted therapy of damaged mihondrial bioenergetics. Perspective therapeutic strategies for damaged mihondria include mihondrial transplantation, plasma therapy, mihondrial nanotherapy, weight reduction in obesity, spa rehabilitation, the influence of molecular hydrogen and oxygen therapy. Targeted therapeutic methods for dysfunctional mihondria and CoQ10 deficiency include supplementation with CoQ10, antioxidants and vitamins.
This volume is intended for researchers and physicians looking for new prospective diagnostic approaches and targeted therapies for dysfunctional mihondria in their patients.